NCT07535190 Endometrial Immune Profile Changes After Autologous Intrauterine PRP Treatment
| NCT ID | NCT07535190 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nadezhda Women's Health Hospital |
| Condition | IVF Patients |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-01-19 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2026-01-19 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The success rate after treatment by in-vitro fertilisation (IVF) strongly depends on the endometrial receptivity, which in turn is strictly connected to the endometrial immune profile. IVF outcome is largely dependent upon endometrial immune cell ratios and their relationship with one another. During the last few years there are several studies and case reports for intrauterine PRP application in patients resulting in a thicker, regenerated endometrium and better immune cell population ratios. In this project, the investigators aim to analyze the effect of autologous intrauterine PRP administration on the endometrial immune profile, endometrial thickness, selected hormone levels (E2, P4) during the mid-luteal phase and IVF outcomes (biochemical and clinical pregnancy).
Eligibility Criteria
Inclusion Criteria: * Participating in Assisted Reproduction Treatment * Having infertility * Having regular menstrual cycles * Embryo transfer of euploid embryos Exclusion Criteria: * Uterine pathologies * Endometrial Bacterial infections * Active endometrial inflammation * Polycystic ovary syndrome * Cancer diagnostics * Positive HIV, HCV or HBV tests * Autoimmune diseases * Recent immune therapy
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07535190 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 50 Years, studying IVF Patients. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07535190 currently recruiting?
Yes, NCT07535190 is actively recruiting participants. Contact the research team at g.stamenov@abv.bg for enrollment information.
Where is the NCT07535190 trial being conducted?
This trial is being conducted at Sofia, Bulgaria.
Who is sponsoring the NCT07535190 clinical trial?
NCT07535190 is sponsored by Nadezhda Women's Health Hospital. The trial plans to enroll 50 participants.